You are here: Industry Insights > iBIO

News List

RubrYc Therapeutics Announces Series A2 Preferred Equity Financing, Collaboration, and RTX-003 License with iBio, Inc. firstwordpharma
August 26, 2021
RubrYc Therapeutics, Inc. ("RubrYc") and iBio, Inc. ("iBio", NYSEA: IBIO) announced today the closing of RubrYc's Series A2 Preferred Financing, and concomitant License and Collaboration Agreements directed towards the research.
iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics firstwordpharma
August 26, 2021
iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company" today announced that it has signed a definitive worldwide exclusive license agreement with RubrYc Therapeutics, Inc., ("RubrYc") for RTX-003, an immunotherapy candidate targeting regulatory T cells (Tregs).
atbtherapeutics Enters Manufacturing Agreement with iBio CDMO contractpharma
December 10, 2020
atbtherapeutics, a biopharmaceutical company building an oncology pipeline using its antibody–toxin-bioengineered “atbody,” has entered a long-term manufacturing agreement with iBio CDMO, a global leader in plant-based biologics manufacturing located ...
iBio to Provide CDMO Services for ATB Therapeutics contractpharma
December 04, 2020
iBio will produce ATB’s bioengineered antibody-toxin fusion proteins.
iBio Enters into Agreement with Safi Biosolutions contractpharma
October 10, 2020
iBio, a biotech innovator and biologics contract manufacturing organization (CMO), has entered into a Master Services Agreement (MSA) with Boston-based Safi Biosolutions to evaluate iBio’s FastPharming System for the expression of key proteins to be ...
iBio Advances COVID-19 Vaccine Candidate contractpharma
September 14, 2020
IBIO-201 induced the production of anti-spike neutralizing antibodies in tests.
iBio Signs License Agreement with Planet Biotechnology for COVID-19 Therapeutic contractpharma
September 02, 2020
iBio Inc., a biotechnology innovator and biologics contract manufacturing organization, has entered into an exclusive worldwide license agreement with Planet Biotechnology Inc. for the development of Planet’s COVID-19 therapeutic candidate, ACE2-Fc.
iBio Receives IBM Clinical Development Solution contractpharma
July 02, 2020
Designed to support clinical COVID-19 vaccine candidates.
iBio Expands COVID-19 Vaccine Collaboration contractpharma
April 14, 2020
Now includes the Infectious Disease Research Institute to help lead pre-clinical development and clinical trial oversight.
iBio Developing Proprietary COVID-19 Vaccine Candidates contractpharma
March 23, 2020
iBio, Inc., a biologics contract manufacturing organization (CMO) and biotechnology company, is progressing towards developing vaccine candidates for preventing infection ...

Previous page 1 2 Next page